What's different is transparency: starting pricing is published by medication, and retatrutide is available as a third option alongside semaglutide and tirzepatide something none of the other four name on their sites
C.Ben-AmorK.SalminenS.de VosW
Many people with obesity have fatty liver disease (NAFLD) without knowing it
J Vis Exp (2015) 101):e53070
To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
And in late 2025, the dominoes started falling